Mindray Reaches 1,000th TE7 Ultrasound System Installation Milestone in North America

/, Press Releases/Mindray Reaches 1,000th TE7 Ultrasound System Installation Milestone in North America

Mindray Reaches 1,000th TE7 Ultrasound System Installation Milestone in North America

Technology Migration Creates Synergism Across All POC and Radiology Platforms Featured at AIUM Annual Conference

Orlando, Fla. – April 9, 2019 – Mindray, a developer of next generation medical technology, announced it has installed its 1000th TE7 portable ultrasound in North America at the annual American Institute of Ultrasound in Medicine (AIUM) conference being held in Orlando, April 6 – 10, 2019. The company is also featuring its latest Gem Series of upgrades to four of its ultrasound systems.

“We are pleased to announce we have reached a significant milestone in our popular TE7 platform with the sale of the 1000th system,” said Maher Elhihi, director of ultrasound marketing, Mindray. “Like other Mindray systems, the TE7 system recently underwent a substantial upgrade, which enhanced image quality and functionality. This allows our customers to stay at the cutting-edge in imaging technology and recognize excellent value for their investment.”

Based on Mindray’s Living Technology™, the Resona 7 (Sapphire), ZS3 (Diamond), M9 (Ruby) and TE7 (Crystal) ultrasound upgrades offer significant enhancements in support of the company’s commitment to providing state-of-the-art ultrasound imaging. The Resona 7 Sapphire edition, powered by ZST+, elevates the system’s performance with advanced capabilities including Sound Touch Elastography and Contrast Enhanced Ultrasound (CEUS).

In addition, the Resona 7 system offers HD Scope, which is an advanced image processing technology made possible by unique and proprietary ZONE Sonography® Technology Plus (ZST+). HD Scope breaks through the constraints of traditional B-mode ultrasound imaging by permitting delineation of subtle or small soft tissue lesions based on the distinct acoustic characteristics of differing tissue types. The Resona 7 also provides STE (Sound touch Elastography) for liver stiffness evaluation with multiple quantitative measures to ensure reproducibility.

From the Resona 7 to the TE7 platforms, Mindray provides contrast-enhanced ultrasound (CEUS) imaging, which uses harmonic and fundamental signals to boost contrast and temporal resolution. The ZST based platforms (Resona 7, ZS3 and Z.One PRO) allow for a lower dose of contrast agent and longer duration of the bubbles. In addition, all Mindray systems offer Z-Tracking™, the ability to track specific transducers used with each patient for infection control efforts, and M-Secure, a robust suite of cybersecurity features.

“The power of our Living Technology is to enable feature and functionality migration throughout our platform base,” said Elhihi. “From our premium cart-based to our point-of-care systems, we are cross-leveraging advances through significant R&D efforts to keep our clinical partners at state-of-the-art ultrasound imaging capabilities.”

 

About Mindray

Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Mindray maintains its global headquarters in Shenzhen, China; North American headquarters in Mahwah, New Jersey; and multiple development facilities and offices in major international markets including an Ultrasound Innovation Center in Silicon Valley. Mindray supplies a broad range of products across three primary business segments, patient monitoring and life support, in-vitro diagnostics, and medical imaging systems. For more information, please visit www.mindray.com.

 

# # #

Media Contact:

Laurie Hallwyler
Mindray
l.hallwyler@mindray.com
650-248-9081

2019-04-10T14:57:10+00:0004-10-2019|